Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
AUSTIN, Texas, March 07, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), today announced financial results for the year ended December 31, 2023 and provided an update on clinical and regulatory activity.
- We expect to be in position to initiate this registrational trial in the fourth quarter, pending positive feedback from the FDA.
- Financial Results for the Year Ended December 31, 2023
Cash Position – Lumos Pharma ended the year on December 31, 2023, with cash, cash equivalents, and short-term investments totaling $36.1 million compared to $67.4 million on December 31, 2022. - Cash on hand as of December 31, 2023, is expected to support operations through the third quarter of 2024.
- ET today to discuss its financial results and to give an update on clinical programs.